Daridorexant (Quviviq) - PsychDB

Last edited on February 25, 2022

Daridorexant (Trade name: Quviviq) is a dual orexin receptor antagonist (DORA) used in the treatment of insomnia disorder.

See also article: Introduction to Pharmacology

Pharmacokinetics of Daridorexant

Absorption
Distribution
Metabolism
Elimination
Half-life

See also article: Cytochrome (CYP) P450 Metabolism

Daridorexant: Cytochrome P450 Metabolism

Substrate of (Metabolized by)
Induces
Inhibits

Dosing for Daridorexant

Starting	25 mg PO daily
Titration
Maximum	50 mg PO daily
Taper

Daridorexant comes in

Daridorexant, like all DORAs, have a theoretical risk for abuse.^[1]^[2]
- Patients with a history of abuse or addiction may be at increased risk for abuse and addiction to DORAs and should be followed carefully

See main article: Geriatric Pharmacology

See main article: Pediatric Pharmacology

See main article: Obstetric and Fetal Pharmacology

See main article: Psychotropic Dosing in the Medically Ill

¹⁾ FDA Review, Lemborexant, Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology

²⁾ Ufer, M., Kelsh, D., Schoedel, K. A., & Dingemanse, J. (2021). Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem. Sleep.